Piramal Pharma Ltd
NSE:PPLPHARMA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Relative Value
The Relative Value of one PPLPHARMA stock under the Base Case scenario is 144.96 INR. Compared to the current market price of 157.86 INR, Piramal Pharma Ltd is Overvalued by 8%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
PPLPHARMA Competitors Multiples
Piramal Pharma Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
P
|
Piramal Pharma Ltd
NSE:PPLPHARMA
|
208.5B INR | 2.9 | -111.8 | 8.7 | 11.6 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
834.9B USD | 23.2 | 136 | 66.4 | 75.5 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.4T DKK | 18.1 | 49.5 | 36.9 | 40.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
350.3B USD | 4.1 | 9.1 | 11.2 | 14.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
327.9B USD | 5.3 | 142.2 | 35.4 | 57.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
193.9B GBP | 5.2 | 39.1 | 175.2 | 279.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
197.4B CHF | 3.4 | 17.2 | 9.7 | 11.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
185.9B CHF | 3.6 | 11.9 | 9.1 | 13.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156B USD | 2.8 | -504.9 | 12.4 | 20 |
You don't have any saved screeners yet
